AR061332A1 - Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa) - Google Patents
Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa)Info
- Publication number
- AR061332A1 AR061332A1 ARP070102537A ARP070102537A AR061332A1 AR 061332 A1 AR061332 A1 AR 061332A1 AR P070102537 A ARP070102537 A AR P070102537A AR P070102537 A ARP070102537 A AR P070102537A AR 061332 A1 AR061332 A1 AR 061332A1
- Authority
- AR
- Argentina
- Prior art keywords
- dgat1
- diacilglicerol
- aciltransferasa
- inhibitor
- oxadiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0611552.1A GB0611552D0 (en) | 2006-06-12 | 2006-06-12 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061332A1 true AR061332A1 (es) | 2008-08-20 |
Family
ID=36745696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102537A AR061332A1 (es) | 2006-06-12 | 2007-06-11 | Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa) |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2041101A1 (fr) |
JP (1) | JP2009539954A (fr) |
KR (1) | KR20090015980A (fr) |
CN (1) | CN101466690A (fr) |
AR (1) | AR061332A1 (fr) |
AU (1) | AU2007259031A1 (fr) |
BR (1) | BRPI0712354A2 (fr) |
CA (1) | CA2653550A1 (fr) |
CL (1) | CL2007001700A1 (fr) |
GB (1) | GB0611552D0 (fr) |
IL (1) | IL195348A0 (fr) |
MX (1) | MX2008015762A (fr) |
NO (1) | NO20084963L (fr) |
TW (1) | TW200815378A (fr) |
UY (1) | UY30404A1 (fr) |
WO (1) | WO2007144571A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
WO2007071966A1 (fr) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido-[4,5-b]-oxazines pour utilisation en tant qu'inhibiteurs de dgat |
KR101456721B1 (ko) | 2006-03-31 | 2014-10-31 | 노파르티스 아게 | 신규 화합물 |
MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
ATE492541T1 (de) | 2006-05-30 | 2011-01-15 | Astrazeneca Ab | Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase |
EP2120911A1 (fr) * | 2007-02-15 | 2009-11-25 | Prosidion Limited | Dérivés d'amide et d'urée pour le traitement de maladies métaboliques |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
BRPI0821274A2 (pt) | 2007-12-20 | 2017-06-13 | Astrazeneca Ab | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica |
EP2408774B1 (fr) | 2009-03-20 | 2014-11-26 | Metabasis Therapeutics, Inc. | Inhibiteurs de diacylglycérol o-acétyltransférase 1 (dgat-1) et leurs utilisations |
EP2443096A1 (fr) | 2009-06-19 | 2012-04-25 | AstraZeneca AB | Carboxamides de pyrazine utiles comme inhibiteurs de la dgat1 |
FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044152A1 (es) * | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
BRPI0519058A2 (pt) * | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
-
2006
- 2006-06-12 GB GBGB0611552.1A patent/GB0611552D0/en not_active Ceased
-
2007
- 2007-06-04 TW TW096120008A patent/TW200815378A/zh unknown
- 2007-06-08 BR BRPI0712354-0A patent/BRPI0712354A2/pt not_active Application Discontinuation
- 2007-06-08 CN CNA2007800217295A patent/CN101466690A/zh active Pending
- 2007-06-08 JP JP2009514875A patent/JP2009539954A/ja active Pending
- 2007-06-08 MX MX2008015762A patent/MX2008015762A/es not_active Application Discontinuation
- 2007-06-08 CA CA002653550A patent/CA2653550A1/fr not_active Abandoned
- 2007-06-08 EP EP07733109A patent/EP2041101A1/fr not_active Withdrawn
- 2007-06-08 KR KR1020087030959A patent/KR20090015980A/ko not_active Application Discontinuation
- 2007-06-08 AU AU2007259031A patent/AU2007259031A1/en not_active Abandoned
- 2007-06-08 WO PCT/GB2007/002097 patent/WO2007144571A1/fr active Application Filing
- 2007-06-11 CL CL2007001700A patent/CL2007001700A1/es unknown
- 2007-06-11 AR ARP070102537A patent/AR061332A1/es not_active Application Discontinuation
- 2007-06-11 UY UY30404A patent/UY30404A1/es not_active Application Discontinuation
-
2008
- 2008-11-17 IL IL195348A patent/IL195348A0/en unknown
- 2008-11-26 NO NO20084963A patent/NO20084963L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2653550A1 (fr) | 2007-12-21 |
EP2041101A1 (fr) | 2009-04-01 |
MX2008015762A (es) | 2009-03-16 |
NO20084963L (no) | 2009-01-07 |
UY30404A1 (es) | 2008-01-31 |
JP2009539954A (ja) | 2009-11-19 |
BRPI0712354A2 (pt) | 2012-06-05 |
TW200815378A (en) | 2008-04-01 |
KR20090015980A (ko) | 2009-02-12 |
WO2007144571A1 (fr) | 2007-12-21 |
GB0611552D0 (en) | 2006-07-19 |
CN101466690A (zh) | 2009-06-24 |
IL195348A0 (en) | 2009-08-03 |
CL2007001700A1 (es) | 2008-01-18 |
AU2007259031A1 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061332A1 (es) | Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa) | |
CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
AR118922A2 (es) | Procesos para la preparación de ácidos de 1,2,4-oxadiazol benzoico | |
CL2011001389A1 (es) | Compuestos derivados de isoxazolina; composicion que comprende a uno de los compuestos; y uso de los compuestos en el control de parasitos. | |
ES2486267T3 (es) | 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas | |
CL2010001369A1 (es) | Compuestos derivados de 3,5-difenilpirazol, 3,5-difenilisoxazol, 2,4-difenilimidazol, 1,4-difenilpirrol, 3,5-difenil-1,2,4-oxadiazol; composicion farmaceutica; kit farmaceutico; utiles para tratar o prevenir una enfermedad relacionada con la agregacion de proteinas y/o neurodegenerativa, tales como enfermedad de prion, parkinson, alzheimer, entre otras. | |
CL2008001170A1 (es) | Compuestos derivados de cromanos y naftaleno sustituidos con un anillo heterociclico; composicion farmaceutica; y su uso en el tratamiento del dolor o dolor nociceptivo agudo o cronico, dolor visceral, dolor inflamatorio y/o neuropatico central o periferico. | |
CL2012001171A1 (es) | Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados. | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
GT201200316A (es) | Forma cristalina de 4- [5-[3-cloro-5-(trifluorometil) fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil-n-[2-0x0-2- [(2,2,-trifluoroetil) amino] etil]-1-naftalenocarboxamida | |
BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2007002967A1 (es) | Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un | |
GT200900260A (es) | Terapia de convinacion anticoagulante con un compuesto que actua como inhibidor del factor xa | |
IL199673A0 (en) | 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes | |
ECSP10010561A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
CL2010001415A1 (es) | Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo | |
CL2009000023A1 (es) | Compuestos derivados de heterociclos de nitrogeno y azufre, moduladores de beta-amiloide; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer, angiopatia amiloide cerebral, hemorragia cerebral, demencia multiinfarto, demencia pugilistica o sindrome de down. | |
UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2009000914A1 (es) | Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica. | |
PE20100083A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |